ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Drug Development Budget Cuts Force Early End To P388 Screening Contracts

January 9, 1987

Survey supports removal of cancer care cuts from Medicare bills.

September 26, 2003

Workshop Suggests Confirmation of Vitamin C Studies

December 7, 1990

Seven Organizations To Use NCI-Army Coding System.

September 1, 2000

Cancer Patient Lobby Outlines Agenda For FDA Reform, Seeks Role In Discussion

June 23, 1995

Congress Passes HHS Appropriations, Includes $9 Billion for NIH, $575 Million Delayed Funding

November 15, 1991